We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 03, 2022

FOLFIRI Plus Ramucirumab vs Paclitaxel Plus Ramucirumab as Second-Line Therapy for Advanced/Metastatic Gastroesophageal Adenocarcinoma With/Without Prior Docetaxel

European Journal of Cancer


Additional Info

European Journal of Cancer
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO
Eur. J. Cancer 2022 Feb 21;165(xx)48-57, S Lorenzen, P Thuss-Patience, C Pauligk, E Gökkurt, T Ettrich, F Lordick, M Stahl, P Reichardt, M Sökler, D Pink, S Probst, A Hinke, TO Goetze, SE Al-Batran

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading